Evidence map›Paper›PMID 33045146›Full record

ArticleCancer cytopathology2021

Molecular alterations in Hürthle cell neoplasms of thyroid: A fine needle aspiration cytology study with cytology-histology correlation.

Syed M Gilani, Julia A Ross, Manju L Prasad, Lynwood Hammers, Guoping Cai, Adebowale J Adeniran

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer cytopathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2022
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Syed M GilaniDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-6185-6062
Julia A RossDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Manju L PrasadDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Lynwood HammersDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Guoping CaiDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-8725-5940
Adebowale J AdeniranDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-9820-632X
Yale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHürthle cell features are frequently observed on the fine-needle aspiration (FNA) cytology of thyroid nodules and often pose a diagnostic challenge because of a significant overlap between cytomorphologic features seen in benign and malignant lesions. Molecular alterations (MAs) associated with these lesions are not well described. The objective of the current study was to evaluate the molecular profile of Hürthle cell lesions classified as Hürthle cell neoplasm (HCN) on cytologic evaluation.

methodsThe authors retrospectively reviewed their electronic database for cytologic diagnoses of HCN from January 1, 2017 to March 31, 2020.

resultsIn total, 279 cases from 275 patients who had a diagnosis of HCN were included in the study. Molecular testing results were available in 85 cases (51 with MAs and 34 without MAs) and, of those, 42 had histologic follow-up available. Eight of 10 malignant cases had MAs, whereas the remaining 2 cases were negative for MAs. The most frequently encountered predominant genetic alterations or classifier findings were chromosome copy number alterations (n = 15), followed by NRAS (n = 8), KRAS (n = 7), suspicious (n = 6), EIF1AX (n = 4), TSHR (n = 3), gene overexpression (n = 3), positive microRNA classifier (n = 2), and 1 each of BRAF K601E, TERT, and HRAS mutations. One hundred thirty-seven cases had histologic follow-up available; of those, 28 were classified as malignant, and 109 were classified as benign (neoplastic and nonneoplastic). The overall risk of malignancy associated with HCN was 20%, and the risk of HCN with MAs was 25%.

conclusionsThe cytologic diagnosis of HCN includes various MAs without any obvious trend, and most malignant cases (80%) have some type of MA.

Indexed as

Adenoma, OxyphilicAgedBiomarkers, TumorBiopsy, Fine-NeedleCytodiagnosisCytological TechniquesFemaleHumansMaleMiddle AgedRetrospective StudiesThyroid NeoplasmsBiomarkers, Tumorfine-needle aspirationHürthle cell lesionsHürthle cell neoplasmmolecular alterationsthyroid

Identifiers

PMID33045146
OpenAlexW3092211304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.